To hear about similar clinical trials, please enter your email below
Trial Title:
Study of miRNA-155 in Acute Leukemia
NCT ID:
NCT05809050
Condition:
Acute Leukemia
Conditions: Official terms:
Leukemia
Acute Disease
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
BM aspirate
Description:
Bone Marrow aspiration & Examination
Arm group label:
AL group
Arm group label:
control group
Summary:
The leukaemias are a heterogeneous group of blood cancers, Acute leukaemia (AL) is caused
by malignant proliferation of blood cells arrested at an immature stage of development,
They are very aggressive diseases that run a rapidly fatal course if not promptly
diagnosed and appropriately treated. Misdiagnosis is very common with delay in diagnosis
and prompt treatment being the causes of high morbidity and mortality in acute
leukaemias.
Although with the continuous improvement of clinical and laboratory diagnosis and
treatment methods, the prognosis of AML has been significantly improved, but there are
still about 70% of patients who cannot survive more than 5 years after diagnosis The
activity of miRNAs in tumors is regulated by the same alterations affecting
protein-coding genes, such as chromosomal rearrangements, genomic amplifications or
deletions or mutations, abnormal transcriptional control, dysregulation of epigenetic
changes and defects in the biogenesis machinery A typical chromosomal rearrangement is a
chromosomal translocation, especially in hematological malignancies, in which it promotes
tumor development and progression by the promoter exchange or by the creation of chimeric
genes translated as fusion proteins. In Acute Myeloid Leukemia (AML) patients with
myeloid/lymphoid leukemia gene (or mixed-lineage leukemia, MLL) rearrangement, by
large-scale genome-wide microarray analysis, it was demonstrated that among 48 selected
miRNAs, 47 of them are increased
Criteria for eligibility:
Study pop:
Group (I): represents the control group ( ITP cases). Group (II): represents the cases of
Acute Leukemia.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- approval to sign an informed written consent, patient with newly diagnosed AL.
Exclusion Criteria:
- Refusal to sign an informed written consent, Cases with Chronic leukemias, Lymphoma
or Leukemic phase of lymphoma or patients on chemotherapy.
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
Accepts Healthy Volunteers
Start date:
April 2023
Completion date:
April 2024
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05809050
